Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2001 Jun 1;61(11):4301-5.

Exploiting Cancer Cell Cycling for Selective Protection of Normal Cells

Affiliations
  • PMID: 11389048
Free article
Review

Exploiting Cancer Cell Cycling for Selective Protection of Normal Cells

M V Blagosklonny et al. Cancer Res. .
Free article

Abstract

Chemotherapy of cancer is limited by its toxicity to normal cells. On the basis of discoveries in signal transduction and cell cycle regulation, novel mechanism-based therapeutics are being developed. Although these cell cycle modulators were designed to target cancer cells, some of them can also be applied for a different purpose, i.e., to protect normal cells against the lethality of chemotherapy. Loss of sensitivity of cancer cells to cell cycle inhibitors can be exploited for selective protection of normal cells that retain this response. Indeed, inhibition of redundant or overactivated pathways (e.g., growth factor-activated pathways) or stimulation of absent pathways in cancer cells (e.g., p53, Rb, and p16) may not arrest cycling of cancer cells. But growth arrest of normal cells will then permit selective killing of cancer cells by cycle-dependent chemotherapy.

Similar articles

See all similar articles

Cited by 49 articles

See all "Cited by" articles

Publication types

Substances

LinkOut - more resources

Feedback